Results 91 to 100 of about 58,665 (304)
Genetic and Pathological Testing Attitudes for Parkinson's Disease in At‐Risk Relatives
Movement Disorders Clinical Practice, EarlyView.Abstract Background Parkinson's disease (PD) is increasingly recognized as a neurodegenerative disorder with a broad clinical spectrum and diverse biomarkers enabling early detection. α‐synuclein seed amplification assays (SAA) and genetic testing now allow identification of PD pathology in asymptomatic individuals.
Tal Weil +5 more
wiley +1 more source
Vitamin D And Omega-3 Long Chain Polyunsaturated Fatty Acids Lowering COVID-19 Cytokines and Anosmia [PDF]
, 2023 openalex +1 more source
Anosmia and dysgeusia in COVID-19: A systematic review
Wellcome Open Research, 2020 Background: This systematic review had three aims: i) to determine the frequency of anosmia (or other smell disorders) and dysgeusia (or other taste disorders) in COVID-19 patients; ii) to determine whether anosmia or dysgeusia are independently ...
Rodrigo M. Carrillo-Larco +1 more
semanticscholar +1 more source
International Journal of Environmental Research and Public Health, 2022 The Coronavirus Disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) resulted in a worldwide pandemic of a highly infectious disease.
Saad N Algahtani +5 more
semanticscholar +1 more source
Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease
Movement Disorders, EarlyView.Abstract Focused ultrasound is rapidly emerging as a novel technology for the development of symptomatic therapies and supporting disease‐modifying treatments for Parkinson's disease (PD). At the forefront of this development is thermoablation using high‐intensity focused ultrasound, an incisionless treatment that has been extensively tested in ...
Rikke Hahn Kofoed +7 more
wiley +1 more source
Resolution of COVID-19 induced anosmia following treatment with ST266
Otolaryngology Case Reports, 2022 Background: Persistent anosmia following COVID-19 disease affects a significant subset of patients. Symptoms of this olfactory dysfunction negatively impact patient quality of life, and effective treatments are lacking; therefore, novel therapies that ...
Devica L. Bhutani +3 more
doaj +1 more source
Smell and taste disorders in the UK: first experiences with a specialised smell and taste outpatient clinic [PDF]
, 2014 Olfactory dysfunction is common, affecting 1‐5% of those under the age of 60 1 and at least 20% of those aged more than 60 years. 2 In many UK centres, the approach to it is variable and routine olfactory testing is not performed, as noted by a recent ...
Carl Philpott, Philpott CM
core +1 more source
Anosmia and dysgeusia associated with SARS-CoV-2 infection: an age-matched case–control study
Canadian Medical Association Journal, 2020 BACKGROUND: Anosmia and dysgeusia have been reported as potential symptoms of coronavirus disease 2019. This study aimed to confirm whether anosmia and dysgeusia are specific symptoms among those who tested positive for severe acute respiratory syndrome ...
A. Carignan +12 more
semanticscholar +1 more source
Stellate Ganglion Block for Anosmia and Dysgeusia Due to Long COVID
Cureus, 2022 Anosmia and parosmia refer to the loss or dysfunction of smell, respectively. Dysgeusia refers to taste disturbance. The coronavirus disease 2019 (COVID-19) pandemic and the subsequent phenomenon of Long COVID syndrome have been associated with an ...
Gaurav Chauhan +3 more
semanticscholar +1 more source
Physiological barriers to oral intake in survivors of critical illness: A scoping review
Nutrition in Clinical Practice, EarlyView.Abstract Oral nutrition is the predominant mode of nutrition delivery on the post–Intensive Care Unit (ICU) ward; yet, it is associated with lower intake than via enteral or parenteral nutrition. There are limited data on barriers that influence oral intake in ICU survivors.
Breanna J. Teleki +4 more
wiley +1 more source